The new product, developed in collaboration with Q-Med AB, is a minimally invasive, injectable gel that can be administered relatively quickly in an outpatient setting without the need for anesthesia.
Oceana plans to focus marketing and medical educational of Solesta on colorectal surgeons, according to the release.
Read the Oceana release on Solesta.
Related Articles on Incontinence:
FDA Gastroenterology and Urology Device Panel Approves Fecal Incontinence Product
10 Managed Care Best Practices for Bariatrics, General Surgery and Gynecology
Allergan Seeks Approval for Lap-Band Surgery for Less Obese Patients
